ImmunityBio, Inc.

US$8.63As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:IBRXHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (16.50%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.17
PE TTM —
TSR TTM 259.79%
Mkt cap US$9.152B
ROIC (69.10%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$11
26.58%
(95.08%)
Hold 3|6|4|11|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.16
0.17
0.18
0.17
16.41%
23.04%
24.79%
10.96%
Revenue$M
430.8
440.1
428.3
417.5
3.45%
5.84%
(2.14%)
(5.98%)
Peers (US$9.152B)
Cap (US$)
PE
8.916B
40.87x
Capital
TTM
5Y
10Y
Leveragex
0.731
0.077
0.069
EBIT/Intx
0.878
0.092
0.107
Own earn%
45.07
(80.86)
(85.83)
Sh yield%
36.53
30.25
35.14
Owners
Insiders/Inst%
7.15
33.92
Short interest%
3.76
SBC / revenue%
5.75
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
3–11
$1 testx
—
Incr. ROIC%
5